Navigation Links
Molecular Devices Continues to Lead the Way in Quality Control and Validation Compliance With a New ISO/IEC 17025 Accreditation

SUNNYVALE, Calif., July 14, 2011 /PRNewswire/ -- Molecular Devices, LLC, a leader in bioanalytical systems for drug discovery & development, life science research, and bioassay/test development, today announced that the American Association for Laboratory Accreditation (A2LA) has accredited the Laboratory Quality System under ISO/IEC 17025 for validation plate calibration and re-calibration processes.


Molecular Devices is one of the first companies servicing the pharmaceutical industry to achieve ISO/IEC 17025 accreditation for validation plate calibration and re-calibration processes for microplate readers. The ISO/IEC 17025 accreditation process is very rigorous, with quality assurance requirements designed to ensure that all calibrations carried out reflect an accurate reading within a defined level of uncertainty. All calibration procedures performed at Molecular Devices comply with the ISO/IEC 17025 criteria; namely, they are performed by competent technicians in a controlled environment, using reference instruments or materials in which the end user can operate an administrative quality system similar to ISO 9001.

Mikey Kindler, Director of Marketing, BioResearch Products, commented: "With any calibration measurement, having confidence in the results is critically important. We are proud to have the ISO/IEC 17025 accreditation for validation plate calibration to help give our customers that confidence." The validation plate calibration and re-calibration processes are an integral part of Molecular Devices' offering. The quality control and validation tools are used to validate instrument and software performance to ensure quality cell lines for assays and to help customers comply with Good Laboratory and Manufacturing Practices (GxP). Molecular Devices was the first to support regulatory compliance for microplate readers, and one of the key products to empower customers in regulated environments is the IQ/OQ/PQ Guidelines to aid system owners in qualifying their SpectraMax® line of microplate readers and liquid handling systems.

The validation plates are the most comprehensive test tools on the market for confirming the industry-leading performance in absorbance, fluorescence, and luminescence.

All of the relevant instrument validation protocols are handled by protocols within award-winning SoftMax Pro software. SoftMax Pro® GxP Compliance Software extends Molecular Devices' leading data acquisition and analysis solution into regulated laboratories working under GMP, GLP, 21 CFR Part 11, and other similar guidelines for secure electronic records.

To find out more about our ISO/IEC 17025 accreditation to our validation plate calibration and re-calibration processes and our validation tools please visit our website

About Molecular Devices: At Molecular Devices we have one focus—our customers. When you become our customer, your needs drive our actions and your success is our concern. Our instruments offer a full spectrum of detection technologies and meet all throughput and content needs. Our goal is to deliver highly relevant bioanalytical products to detect biology, decode data, and drive discovery.

Global Sales & Support Offices: N America: 1 800 635 5577, Brazil: +55 11 3616 6607; UK: +44 118 944 8000; Germany: +49 89/96 05 88 0; China: +86 10 6410 8669 (Beijing), +86 21 33721088 (Shanghai); Japan: +81 6 6399 8211 (Osaka), +81 3 5282 5261 (Tokyo); S Korea: +82 2 3471 9531

All products are FOR RESEARCH USE ONLY. Not for Use in Diagnostic Procedures.

All trademarks are the property of Molecular Devices, Inc.

SOURCE Molecular Devices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
2. Genetix Joins Molecular Devices: Combining Businesses to be in a Better Position to Serve Customers
3. Amsterdam Molecular Therapeutics Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients
4. Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
5. PharmacoFore, Inc. Announces Positive Results from a Phase I Clinical Study of Its Hydromorphone Bio-Activated Molecular Delivery™ System, and Upcoming Presentation at the 2011 BIO Business Forum During the Annual BIO International Convention in Was
6. Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis
7. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
8. ImaginAb, Inc. Announces Availability of Custom Protein Radiolabeling Services for Molecular Imaging
9. Medco Partners With MolecularMD on Personalized Medicine Program for Chronic Myeloid Leukemia
10. The World Leader in Molecular Breast Imaging to Premiere Largest Detector in the Industry
11. Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
Post Your Comments:
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
Breaking Medicine News(10 mins):